Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04884035
Title Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphom
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene

B-cell lymphoma


CC-99282 + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.